Imunon Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Imunon Stock Summary

Imunon competes with Exicure, Cyclacel Pharmaceuticals, DiaMedica Therapeutics, Senti Biosciences, and SAB Biotherapeutics. Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey. Imunon operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 29 people.

Imunon Key Financial Ratios

Imunon Key Balance Sheet Accounts

Imunon Key Income Statement Accounts

Imunon Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Imunon's current stock value. Our valuation model uses many indicators to compare Imunon value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Imunon competition to find correlations between indicators driving Imunon's intrinsic value. More Info.Imunon Inc is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Imunon's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Imunon's earnings, one of the primary drivers of an investment's value.

Imunon Inc Systematic Risk

Today, most investors in Imunon Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Imunon's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Imunon growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Imunon help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Imunon Inc. We use our internally-developed statistical techniques to arrive at the intrinsic value of Imunon Inc based on widely used predictive technical indicators. In general, we focus on analyzing Imunon Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Imunon's daily price indicators and compare them against related drivers.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Imunon Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Imunon. If investors know Imunon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Imunon listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Imunon Inc is measured differently than its book value, which is the value of Imunon that is recorded on the company's balance sheet. Investors also form their own opinion of Imunon's value that differs from its market value or its book value, called intrinsic value, which is Imunon's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Imunon's market value can be influenced by many factors that don't directly affect Imunon's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Imunon's value and its price as these two are different measures arrived at by different means. Investors typically determine if Imunon is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Imunon's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.